Veracyte (VCYT) The 44th Annual William Blair Growth Stock Conference summary

Business overview and vision

• Focused on transforming cancer care globally, expanding from endocrinology to a broad oncology portfolio.

• Over 450,000 patients served in 35+ countries; tests used in 35 clinical trials and cited in 500+ publications.

• Core belief: more genomic and clinical data leads to better patient outcomes.

• Diagnostics platform leverages bioinformatics, AI, and evidence cycles to drive adoption and reimbursement.

• Platform enables expansion across the cancer care continuum and supports growth in new indications.

Strategic growth drivers

• Four key drivers: expanding Decipher and Afirma share, launching three new IVD tests in Europe, Percepta Nasal Swab for lung cancer, and MRD test via C2i acquisition.

• Decipher Prostate received highest NCCN guideline rating, with 30% YoY test volume growth in Q1.

• Afirma has helped 175,000+ patients avoid unnecessary surgery; 14,000 tests delivered in Q1 with 14% revenue growth.

• Both Decipher and Afirma target market penetration increases to 80% from current 35% and 60%, respectively.

• IVD roadmap includes Prosigna and Decipher launches in 2025, Percepta Nasal Swab in 2026.

Product innovation and evidence generation

• Decipher’s NCCN guideline inclusion and GRID data platform drive adoption and research.

• Afirma’s performance validated by meta-analysis, increasing clinical reliance.

• Percepta Nasal Swab offers non-invasive lung nodule risk assessment; clinical validation published in CHEST.

• MRD test leverages whole genome sequencing for earlier detection and rapid, patient-specific results.

• Ongoing clinical studies and payer engagement support reimbursement and market expansion.